LAIYANG, China, Sept. 2 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (the “Company”, “Jiangbo”), a U.S. pharmaceutical company with its principal operations in the People’s Republic of China, today announced that Ms. Elsa Sung, the Company’s CFO will present at the upcoming Rodman & Renshaw Annual Global Investment Conference to be held on September 9-11 at the New York Palace Hotel in New York City.
The date, time and location of Jiangbo Pharmaceuticals’ presentation at the conference are as follows:
A replay of the presentation will be available for 90 days following the live presentation using the same link and will also be available on the Company’s website at http://www.jiangbopharma.com .
During the conference, the Company will be available to meet with analysts and portfolio managers. Interested parties and investors who wish to meet with Jiangbo Pharmaceuticals’ management may contact mwoodson@rodm.com or call (212) 430-1782. Participation in the Rodman and Renshaw Annual Global Investment Conference is by invitation only.
About Rodman & Renshaw, LLC
Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant capital needs, along with research and sales and trading services to investor clients. Rodman is a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets according to PrivateRaise a service of DealFlow Media Inc. and Sagient Research Systems, Inc.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People’s Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com
Safe Harbor Statement
Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.
SOURCE Jiangbo Pharmaceuticals, Inc.
CONTACT: Elsa Sung, CFO of Jiangbo Pharmaceuticals, Inc., +1-954-727-8435,
elsasung@jiangbo.com; Or Crocker Coulson, President of CCG Investor
Relations, Inc., +1-646-213-1915, crocker.coulson@ccgir.com
Web site: http://www.jiangbopharma.com/
http://www.wsw.com/webcast/rrshq15/jgbo.ob/
